Xi'an Faithful BioTech Co., Ltd. is selling Tirzepatide Raw Powder. Please feel free to contact us if you have any purchase needs.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
I. Core Attributes:
Chemical Nature and Preparation Characteristics of a Dual-Target Product Telpotripeptide is a synthetically produced fatty acid-modified peptide Product. Chemically, it is a polypeptide molecule composed of 39 amino acids, containing a C20 fatty acid tail. This unique structure allows it to bind efficiently to albumin, significantly prolonging its duration of action in vivo. Its molecular formula is C₂₂₁H₃⁴₄N₆₀O₇₁S, with a molecular weight of approximately 5100 Da.
As a polypeptide product, the preparation of Telpotripeptide relies on high-precision solid-phase synthesis technology. The core process includes three key steps: amino acid sequence assembly, fatty acid modification, and purification. The synthesis of its active pharmaceutical ingredient (API) requires extremely high control over the reaction environment, necessitating strict control of temperature, pH, and reaction time to avoid amino acid mismatch. The formulation excipients contain only inert components such as physiological saline and phosphates, ensuring product safety while simplifying the production process. Currently, Eli Lilly has established a global production system, achieving over 99% plasma protein binding through patented synthesis processes, laying the foundation for long-acting Product delivery.
II. R&D Context: A Decade of Breakthrough from Target Innovation to Global Approval
The development of telpotetide began in the 2010s, with its core R&D logic stemming from in-depth exploration of metabolic regulation mechanisms. At that time, single-target GLP-1 receptor agonists (such as smegglutide) had proven their value in the field of blood sugar control, but suffered from limited weight loss effects and a single mechanism of action. Eli Lilly's R&D team discovered that GIP (glucose-dependent insulinotropic peptide) receptors and GLP-1 receptors have a synergistic effect in metabolic regulation; activating both receptors could achieve a "1+1>2" therapeutic effect. This innovative idea became the starting point for the development of telpotetide.
2022 marked a key milestone for Zepbound: In April, data from the SURMOUNT series of clinical trials were released, confirming its significantly superior weight loss effect compared to existing products; on May 13th, it received FDA approval in the US, marketed under the brand name Mounjaro for glycemic control in patients with type 2 diabetes, achieving $483 million in revenue in its first year. The development process accelerated in 2023. In June, research published in *Nature Metabolism* confirmed the scientific basis of its dual-receptor activation mechanism; in November, the FDA further approved its weight loss indication, updating the brand name to Zepbound, making it the first prescription product to achieve an average weight loss of over 20% in Phase 3 clinical trials.
In the Chinese market, the approval process for Zepbound progressed simultaneously: a new indication was submitted for marketing approval in August 2023, and it received approval from the National Medical Products Administration (NMPA) on May 21, 2024. In December of the same year, related diagnosis and medication services were available on domestic e-commerce platforms, rapidly connecting with clinical needs. As of 2025, its indications expansion research has covered areas such as non-alcoholic fatty liver disease (NASH), heart failure, and obstructive sleep apnea, forming a multi-dimensional R&D pipeline.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
III. Pharmacological Mechanism: A Revolution in Metabolic Regulation Through Dual-Receptor Synergistic Action
The core advantage of telpolide lies in its simultaneous activation of both GIP and GLP-1 incretin receptors, achieving metabolic regulation through a triple-action pathway. This mechanism represents a qualitative breakthrough compared to single-target products. Research published in *Nature Metabolism* confirms that in human pancreatic islet cells, GIP receptor activation is crucial for insulin secretion, while GLP-1 receptor activation focuses on appetite suppression. Together, they construct a more comprehensive metabolic regulatory network.
Firstly, regarding blood glucose control: GLP-1 receptor activation promotes insulin secretion from pancreatic β-cells while inhibiting glucagon secretion from α-cells, achieving glucose-dependent blood glucose regulation and avoiding the risk of hypoglycemia. GIP receptor activation further enhances insulin sensitivity, especially strengthening the hypoglycemic effect in hyperglycemic states. Clinical data show that in patients with type 2 diabetes, telpolide reduces glycated hemoglobin (HbA1c) by 1.6%-2.1%, superior to the hypoglycemic effect of smegglutide.
Secondly, the mechanism of weight loss is as follows: GLP-1 receptor activation suppresses appetite and delays gastric emptying by acting on the central nervous system, thus reducing calorie intake; GIP receptor activation uniquely increases energy expenditure and promotes lipolysis. This "bidirectional regulation" mode results in significant weight loss. The SURMOUNT-5 study showed that the 15mg dose group achieved an average weight loss of 22.8 kg over 72 weeks, a weight loss rate of 20.2%, which is 1.47 times that of the semaglutide group (13.7%).
Furthermore, semaglutide has a protective effect on metabolically related organs, improving hepatic steatosis by regulating inflammatory factor levels and reducing the risk of cardiovascular disease, providing a pharmacological basis for expanding its indications.
IV. Clinical Applications: Breakthroughs in Multiple Scenarios from Blood Sugar Control to Weight Loss
Currently, telpotetide's core indications have formed a "dual-pillar" structure: In the treatment of type 2 diabetes, it is suitable for adult patients with poor diet and exercise control, especially those with obesity, achieving simultaneous blood sugar management and weight control; in the treatment of obesity, it is the first prescription product to achieve an "average weight loss of over 20%" for patients with a BMI ≥ 30 or BMI ≥ 27 and obesity-related complications.
Clinical application data show significant advantages: In diabetic patients, a 5mg dose treated for 72 weeks resulted in a 15.7% weight loss, addressing both blood sugar control and weight loss needs; in patients with simple obesity, the 15mg dose group saw an average waist circumference reduction of 18.4cm, far superior to the 13.0cm reduction in the smegglutide group, and 64.6% of patients achieved a weight loss rate of ≥ 15%, 1.6 times that of the control group (40.1%). In December 2024, its indication for the treatment of obstructive sleep apnea was approved, making it the first GLP-1 product for this disease, further expanding its clinical value.
Regarding usage guidelines, telpotetide is administered via subcutaneous injection once weekly. The initial dose is usually 2.5 mg, gradually adjusted to the target dose based on tolerability, with a maximum dose not exceeding 15 mg. Common adverse reactions include gastrointestinal reactions such as nausea, vomiting, and diarrhea, which mostly occur at the beginning of treatment and subside with the course of treatment. The incidence of side effects is slightly higher in the high-dose group, but overall tolerability is better than traditional weight-loss products. During treatment, it is necessary to avoid indiscriminate use with insulin or other hypoglycemic products to prevent the risk of hypoglycemia.
V. Industry Status: A Duopoly Dominated by a Hundred-Billion-Dollar Market
The global market presents a duopoly competition between Eli Lilly and Novo Nordisk. Eli Lilly, leveraging the efficacy advantages of its telpotetide, rapidly captured market share. As of the third quarter of 2025, its share of GLP-1 prescriptions in the US reached 57.9%, surpassing semaglutide (41.7%) for the first time. In its first year on the market, telpotetide generated $483 million in revenue in 2022, and by the first quarter of 2025, its quarterly revenue had reached $6.15 billion. While still lower than semaglutide's $8.011 billion, its growth momentum was stronger.
In terms of production layout, Eli Lilly has built a global production network centered in Europe and the US, supplemented by the Asia-Pacific region. In China, it has rapidly implemented treatment services through cooperative models. In December 2024, several domestic e-commerce platforms opened telpotetide treatment and medication channels, accelerating market penetration. Regarding cost and pricing, its monthly treatment cost is approximately RMB 7,700, 20% lower than semaglutide, making its price advantage a crucial support for market expansion.
The domestic market presents a pattern of "original drug leadership + generic drug catch-up." Hengrui Medicine's GIP/GLP-1 dual-target agonist HRS9531 has completed Phase III clinical trials, showing an average weight loss of 19.2% over 48 weeks in the 6mg dose group, and its marketing application has been accepted. Similar products from companies like Innovent Biologics and CSPC Pharmaceutical Group have also entered late-stage clinical trials, focusing on dual-target combinations such as GLP-1/GIP and GLP-1/GCG. The next 3-5 years will see a peak in generic competition.
In terms of market size, the global GLP-1 drug market reached $51.8 billion in 2024, a year-on-year increase of 42%, and is projected to exceed $60 billion in 2025 and reach over $80 billion by 2030. Among them, telpotetide, with its potential for expanding indications, is expected to reach $41 billion in sales in the US market by 2028.
VI. Regulatory Policies: Global Differentiated Controls and Market Access Progress
Regulatory agencies in various countries have developed differentiated policy systems regarding the efficacy verification and risk management of telpotetide. The US FDA adopted a "fast track + priority review" model, quickly approving its dual indications of blood sugar control and weight loss based on solid data from the SURMOUNT series trials, but requiring Eli Lilly to conduct long-term cardiovascular safety monitoring. The EU EMA focused more on the risk warnings of gastrointestinal side effects during the approval process, requiring the product instructions to clearly state the principles for dose adjustment.
Chinese regulatory agencies adopted a "clinical value-oriented" approval path, approving its marketing in May 2024 based on global multicenter data, while requiring supplementary long-term safety data for the Chinese population. Currently, telpotetide is not included in the national medical insurance catalog, making medical insurance negotiations a focus of market attention. It is expected that its pricing will reference the medical insurance payment standards of semaglutide, trading price concessions for greater market coverage.
Regulatory focus is concentrated on three aspects: first, the safety of long-term use, especially the potential risk to thyroid C-cell tumors, for which the EU has issued risk warnings; second, abuse control to prevent unauthorized use by non-indication groups; and third, supply chain security, as Eli Lilly experienced short-term supply shortages due to surging demand, and regulatory agencies have required it to strengthen its production capacity reserves.
VII. Development Trends: An Innovation Path of Opportunities and Challenges
The development of telpotetide faces multiple opportunities. Expanding indications is the core growth engine. Currently, its clinical research in areas such as NASH, heart failure, and chronic kidney disease is progressing smoothly, and successful approval will open up a market worth hundreds of billions. Formulation innovation will also improve the convenience of medication. Eli Lilly has already started the development of oral formulations to address the compliance issues of injectable administration, while the exploration of long-acting formulations is expected to extend the dosing cycle to once every two weeks.
Challenges are equally significant. Patent barriers will gradually disintegrate, with its core patents expected to expire after 2030. Domestic generic drug companies have already made advance preparations, and future market competition will shift from "efficacy competition" to "cost control." The need for side effect optimization is urgent; gastrointestinal reactions remain a major factor affecting compliance. Next-generation products need to maintain efficacy while reducing the incidence of adverse reactions. Furthermore, competition in the GLP-1 field is intensifying. Although companies such as AstraZeneca and Pfizer have terminated product development, the rapid catch-up by domestic companies such as Innovent and Hengrui will reshape the market landscape.
The direction of technological development has shown a clear trend: multi-target combinations have become the mainstream of research and development, such as GLP-1/GIP/GCG three-target agonists which have entered the early stage of clinical trials; the application of precision medicine is accelerating, and the most suitable population is screened through gene testing to achieve "personalized drug delivery"; drug delivery technology innovation continues to break through, and new dosage forms such as microsphere formulations and transdermal patches are under development.
Conclusion
The advent of telpolide is not only a technological breakthrough in the treatment of metabolic diseases, but also a paradigm shift in the research and development of peptide products. Its dual-target synergistic mechanism validates the scientific validity of multi-receptor regulation, driving global pharmaceutical companies to shift from a "single-target in-depth study" to a "multi-target synergistic" R&D approach. Facing a market worth hundreds of billions, telpolide needs to address side effects, compliance, and cost issues while maintaining its efficacy advantages. In the future, with the continuous expansion of indications, ongoing innovation in formulation technology, and the gradual implementation of medical insurance access, telpolide is expected to become a "benchmark product" in the metabolic product market, bringing new treatment hope to billions of patients with metabolic diseases worldwide, while simultaneously propelling Chinese innovative pharmaceutical companies from "follower" to "leader" in the GLP-1 field.
As a provider of premium Tirzepatide CAS 654671-78-0, Xi'an Faithful BioTech Co., Ltd. leverages state-of-the-art production technology and rigorous quality assurance to meet international pharmaceutical requirements. Our dedication to superior quality, cost-effective pricing, and tailored technical support has made us the preferred collaborator for healthcare professionals and researchers worldwide. To obtain detailed specifications and application guidance for our Tirzepatide Powder, contact our technical team at sales4@faithfulbio.com and explore how our offerings can enhance your product formulations.